NIKKEI 225
39,665.02 +81.94 (+0.21%) HANG SENG
17,718.61 +2.11 (+0.01%) CRUDE OIL
81.93 +0.39 (+0.48%) GOLD FUTURES
2,336.20 -3.40 (-0.15%) DOW
39,118.86 -45.24 (-0.12%) Bitcoin GBP
50,133.82 +2,092.27 (+4.36%)
VIR Mar 2025 15.000 call
- Business Wire
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
SAN FRANCISCO, June 26, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection. Tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, are currently being evaluated in the Company’s
- Simply Wall St.
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- Zacks
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
